Healthpeak Properties, Inc. (FRA:HC5)
Germany · Delayed Price · Currency is EUR | Market Cap | 13.65B +31.0% |
| Revenue (ttm) | 2.49B +2.7% |
| Net Income | 192.22M -20.5% |
| EPS | 0.28 -19.7% |
| Shares Out | n/a |
| PE Ratio | 71.00 |
| Forward PE | 260.69 |
| Dividend | 1.05 (5.31%) |
| Ex-Dividend Date | Jul 20, 2026 |
| Volume | 200 |
| Open | 19.56 |
| Previous Close | 19.57 |
| Day's Range | 19.53 - 19.73 |
| 52-Week Range | 13.30 - 19.78 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Healthpeak Properties
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery. Healthpeak Properties, Inc. is based in Denver, Colorado. Healthpeak Properties, Inc. was incorporated in 1985 in Maryland. [Read more]
Financial Performance
In 2025, Healthpeak Properties's revenue was $2.82 billion, an increase of 4.52% compared to the previous year's $2.70 billion. Earnings were $70.51 million, a decrease of -70.91%.
Financial numbers in USD Financial StatementsNews
Best 3 REITs to own for reliable passive income in 2026
As central bank policy stabilizes and real estate valuations recalibrate, income-focused investors are increasingly looking toward real estate investment trusts (REITs) to secure durable cash flows. H...
Healthpeak Properties, Brookfield Asset Management form $2.1B joint venture
Healthpeak Properties (DOC) and Brookfield Asset Management (BAM) announced the formation of a long-term strategic capital partnership through a joint venture involving a portfolio of outpatient medic...
Healthpeak Properties and Brookfield Form a $2.1 Billion Strategic Joint Venture
DENVER & NEW YORK--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak") and Brookfield Asset Management (NYSE: BAM, TSX: BAM) (“Brookfield”), today announced the formation of a long...
Top 10 Dividend Stocks to Buy in 2026
In this bonus episode of The Morning Filter podcast, co-hosts Dave Sekera and Susan Dziubinski talk dividend stock investing. They unpack the performance of dividend stocks during the first half of 20...
Healthpeak Properties price target raised to $22 from $20 at Wells Fargo
Wells Fargo raised the firm’s price target on Healthpeak Properties (DOC) to $22 from $20 and keeps an Equal Weight rating on the shares as part of an earnings preview…
Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Third Quarter of 2026
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC) ("Healthpeak"), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on July 9...
Healthpeak Properties price target raised to $21.50 from $19 at UBS
UBS raised the firm’s price target on Healthpeak Properties (DOC) to $21.50 from $19 and keeps a Neutral rating on the shares.
Healthpeak Properties initiated with an Equal Weight at Barclays
Barclays initiated coverage of Healthpeak Properties (DOC) with an Equal Weight rating and $23 price target While initiating coverage of six healthcare REITs, the analyst tells investors that healthca...
Healthpeak Properties price target raised to $24 from $21 at Mizuho
Mizuho analyst Vikram Malhotra raised the firm’s price target on Healthpeak Properties (DOC) to $24 from $21 and keeps an Outperform rating on the shares.
Healthpeak Properties price target raised to $21 from $18 at JPMorgan
JPMorgan raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $18 and keeps a Neutral rating on the shares. The firm updated the company’s model. Published first…
Healthpeak Properties Publishes Its 15th Annual Corporate Impact Report
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. ("Healthpeak") (NYSE: DOC) announced today the release of its 15th annual 2025 Corporate Impact Report (the "Report"). The Report highlights Health...
Healthpeak Properties resumed with a Market Perform at Raymond James
Raymond James resumed coverage of Healthpeak Properties (DOC) with a Market Perform rating and no price target The firm sees flattish earnings growth into the second half of 2027 for…
Healthpeak Properties Announces Dates of Second Quarter 2026 Earnings Release, Conference Call, and Webcast
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report second quarter 2...
Healthpeak Properties price target raised to $24 from $20 at BMO Capital
BMO Capital raised the firm’s price target on Healthpeak Properties (DOC) to $24 from $20 and keeps an Outperform rating on the shares as part of a broader research note…
Healthpeak Properties downgraded to Equal Weight at Morgan Stanley
As previously reported, Morgan Stanley analyst Ronald Kamdem downgraded Healthpeak Properties (DOC) to Equal Weight from Overweight with a price target of $22, up from $20. While “encouraged” by the…
Healthpeak Properties downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Ronald Kamdem downgraded Healthpeak Properties (DOC) to Equal Weight from Overweight with a price target of $22, up from $20.
EU clears Arla's DMK, DOC buyout, citing no competition concerns
The European Union on Thursday approved Arla Foods' acquisition of Germany's DMK and Dutch cooperative DOC without conditions, saying the deal would not harm competition in the European Economi...
Healthpeak Properties price target raised to $21 from $19 at Scotiabank
Scotiabank raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $19 and keeps a Sector Perform rating on the shares. The firm is updating its estimates for…
Healthpeak Properties price target raised to $20 from $18 at Morgan Stanley
Morgan Stanley analyst Ronald Kamdem raised the firm’s price target on Healthpeak Properties (DOC) to $20 from $18 and keeps an Overweight rating on the shares.
Healthpeak Properties price target raised to $21 from $19 at Baird
Baird analyst Wesley Golladay raised the firm’s price target on Healthpeak Properties (DOC) to $21 from $19 and keeps an Outperform rating on the shares. The firm updated its model…
Healthpeak Properties price target raised to $19 from $17 at UBS
UBS raised the firm’s price target on Healthpeak Properties (DOC) to $19 from $17 and keeps a Neutral rating on the shares.
Healthpeak Properties price target raised to $20 from $17.50 at Citi
Citi raised the firm’s price target on Healthpeak Properties (DOC) to $20 from $17.50 and keeps a Neutral rating on the shares.
Healthpeak Properties downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Healthpeak Properties (DOC) to In Line from Outperform with a price target of $21, up from $20. While the quarter was complicated by the Janus Living IPO…
Healthpeak Properties Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution with the Janus Living IPO, robust leasing in all segments, and accretive capital actions. Guidance was raised as senior housing and outpatient medical outperformed, while life science occupancy and pipeline improved.